CAR-T cell therapy for prostate cancer

[jeetu_g27]

Hii

I have heard and read about CAR-T cell therapy . It may be most effective treatment for cancer as it uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer . Though this is not available for commercial and common people use in India and mostly in trial stage. It is quite expensive but if it is 100% accurate , many can give it a chance

Anyone's experience through trial phase or treatment can be a help.

[God_Loves_Me]

It is NOT 100% accurate cure

I am not sure about INDIA. In usa many clinical trials that can help you with CART Therapy. One important thing is understand side effects, I think most of patients shared cytokine release is serious side effects. Please learn about before sign up.

[jeetu_g27 in reply to God_Loves_Me]

Thanks for the reply There are some posts and videos over internet who are claiming it to be 100% cure . will try to learn more and more

[j-o-h-n in reply to jeetu_g27]

Death = 100% cure.

Good Luck, Good Health and Good Humor.

j-o-h-n

[Mascouche]

I asked the perplexity.ai : "How effective CAR-T cell therapy for prostate cancer?". It's answer is below but in short, it is early days.

***

Based on the information provided in the search results, CAR-T cell therapy is showing promise in treating prostate cancer, but its effectiveness is still being evaluated in clinical trials. Here are the key points:

The provided search results cover preclinical and early-phase clinical trials evaluating CAR-T cell therapy targeting prostate cancer.

In preclinical models using prostate cancer cell lines and mouse models, targeting PSCA (prostate stem cell antigen) with CAR-T cells showed anti-tumor effects .

A phase 1 clinical trial (NCT03063760) evaluated a PSCA-targeting CAR-T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial met its primary endpoint of safety and showed some anti-tumor effects .

Another phase 1 trial (NCT03330130) evaluated a different CAR-T therapy targeting PSMA (prostate-specific membrane antigen) in patients with metastatic castration-resistant prostate cancer. The trial met its primary endpoint of safety and showed some anti-tumor effects .

The provided search results cover preclinical and early-phase clinical trials evaluating CAR-T cell therapy targeting prostate cancer.

In preclinical models using prostate cancer cell lines and mouse models, targeting PSCA (prostate stem cell antigen) with CAR-T cells showed anti-tumor effects .

A phase 1 clinical trial (NCT03063760) evaluated a PSCA-targeting CAR-T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial met its primary endpoint of safety and showed some anti-tumor effects .

Another phase 1 trial (NCT03330130) evaluated a different CAR-T therapy targeting PSMA (prostate-specific membrane antigen) in patients with metastatic castration-resistant prostate cancer. The trial met its primary endpoint of safety and showed some anti-tumor effects .

The provided search results cover preclinical and early-phase clinical trials evaluating CAR-T cell therapy targeting prostate cancer.

In preclinical models using prostate cancer cell lines and mouse models, targeting PSCA (prostate stem cell antigen) with CAR-T cells showed anti-tumor effects .

A phase 1 clinical trial (NCT03063760) evaluated a PSCA-targeting CAR-T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial met its primary endpoint of safety and showed some anti-tumor effects .

Another phase 1 trial (NCT03330130) evaluated a different CAR-T therapy targeting PSMA (prostate-specific membrane antigen) in patients with metastatic castration-resistant prostate cancer. The trial met its primary endpoint of safety and showed some anti-tumor effects .

In summary, while CAR-T cell therapy is showing promise in treating prostate cancer, its effectiveness is still being evaluated in clinical trials. The provided search results cover preclinical and early-phase clinical trials evaluating CAR-T cell therapy targeting prostate cancer.